chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Caller tested positive after the first shot/COVID; Caller tested positive after the first shot/COVID; He had a little bit of a cough but thought it was allergies; He had chills and sensitive skin; He had chills and sensitive skin; This is a Spontaneous report from a Pfizer sponsored program. A contactable consumer (patient) reported a male patient received first dose of bnt162b2 (Pfizer-BioNTech COVID-19 mRNA vaccine, Lot Number and Expiration Date unknown) via an unspecified route of administration on 22Jan2021 at single dose for COVID-19 immunisation. The patient's medical history and concomitant medications was not reported. Patient said he was fortunate to have received the Pfizer COVID Vaccine. He was retired Navy. He received the dose at Hospital on 22Jan2021. Apparently at that time he had initial symptoms of COVID. He had a little bit of a cough but thought it was allergies. After the vaccine, the next few days his symptoms developed. His cough got worse. He had chills and sensitive skin. On 25Jan2021 he was tested for COVID. He got his results this morning and they were positive. He has been talking with online nurses and doctors. He has specific questions for Pfizer. Patient wanted to know about could the shot itself have contributed to a positive test from forming antibodies. Second dose was scheduled for 12Feb2021. Wanted to know if he should get that one. He pulled his back coughing too hard. He was headed to the Emergency Room (ER) to get treated because he cannot go anywhere else due to COVID. The outcome of the events was unknown with treatment received.  Information on the batch/Lot number has been requested.
Reaction of L deltoid to flu vaccine on 12-8-05. 6x4 cm pink and slight raised.  No temp.  No allergies to egg.
Patient experienced swelling and tenderness in the right leg 22 hours after administration of the vaccine. Swelling present from hip/groin area to the knee. Right thigh was the site of administration.  Reddness, warmth also present in the right leg. accompanied by low grade fever present after about 14 hours post vaccine. Patient was treated with a 5 day period of pediapred with the swelling and reddness dissappearing after 48 hours of medication treatment.
he missed his second shot schedule last month; This is a spontaneous report from a contactable consumer or other non hcp. A male patient of an unspecified age received first dose bnt162b2 (BNT162B2, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on an unspecified date as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient experienced he missed his second shot schedule last month on an unspecified date. The outcome of the event product dose omission issue was unknown.  Follow-up (13May2021): Follow-up attempts completed. No further information expected.
This spontaneous report was received from a nurse regarding multiple unspecified patients of unknown age and gender. The patient's pertinent medical history, drug reactions or allergies and concomitant therapies were not reported. On unknown dates, the patients were vaccinated with an improperly stored doses of PROQUAD (Merck) (dose and route were not reported, lot # L030586, expiry date: 10-FEB-2017). There was no adverse effects reported. This is one of the several reports from the same source. Lot number L030586 has been verified to be a valid lot number for PROQUAD (Merck). Follow up information was received on 12-FEB-2016, from health professional regarding a 5 year old male patient. On 04-DEC-2016, the patient was vaccinated with a dose of PROQUAD (Merck). This is one of several reports received from the same reporter, Additional information has been requested.
12/30/21 pt admitted to hosp with increased confusion and weakness; diagnosed with UTI/encephalopathy; initial COVID test was negative, but then pt had a positive COVID test on 1/2/22; limited medical records sent; per death certificate, pt died in the hospital with Severe COVID Pneumonia being one of the causes of death
Patient's mother called on 7/19/18 to notify us that she had taken patient to the ER for fever the evening of 7/18/18. ER visit found no cause for elevated temperature and she was instructed to follow up with PCP the following day. Patient was seen in office on 7/19/18 and noted to have rectal temperature of 101.6 at 0945, with TYLENOL on board given by mother at home at 0800. PCP also noted patient was dyspneic and using accessory muscles to breathe. Patient was sent to ER again on 7/19/18. ER report showed elevated WBC, but no other possible cause for fever. Diagnosis at ER was fever of unknown origin. Patient has not followed up with our office since, although, we did call patient's mother on 7/20/18 to check on him. Mother reported patient no longer had a fever and breathing had returned to normal.
Patient felt in the heart with symptoms. Had Parkinson like symptoms and blood pressure dropped from 110/70 to 70/50. He said he was tired and fell asleep for more than 12 hrs.
The evening after receiving HPV, swelling of hands, pink warm splotches on her hands, fingers and extremities, lesions waxed and waned through the night. Ended up having swelling of hands, feet and face the next several days making it hard to walk. Lip swollen, used Claritin and Benadryl.
A 68-year old female patient, who had no illness at the time of vaccination, allergies included Prednisone and concomitant medication were not reported, had received an intramuscular dose of FLUZONE HD (lot number: U4498BA) on left arm on 22 October 2012. On 22 October 2012, within an hour of vaccination, the patient experienced metallic taste in mouth which lasted about an hour. Later on same day, the patient presented discomfort in throat. The patient was observed at the pharmacy. The corrective treatments and laboratory investigations were not reported. At the time of this report, the patient had not recovered. Follow up information received fro a healthcare professional on 25 January 2013. On 22 October 2012 approximately at 7-8 PM that evening, the patient's eyes turned red. The patient's concomitant medication included Lorazepam 0.5 mg tablets. On an unspecified date the following day, all symptoms were resolved. Documents  held by sender: none.
The vaccine of DTAP was administered in left deltoid in the morning of January 26th, 2017. Later that evening, I developed a fever of 103 and severe joint and body pain and visible red, hot rash at injection site and arm. I was unable to move on my own and needed assistance to go to the restroom and get up out of the bed. I was also pregnant with my first pregnancy at 32-35 weeks. My arm and joints were swollen. The pain was excruciating to the point of crying. I had a difficult time breathing. When I went the next day to the office of OBGYN, - I was seen by his PA. I was assisted by my mother in law who helped get me to the Doctors office as I needed help walking and moving. I was still running a fever but was low-grade as I had taken a fever reducer that is said to be safe during pregnancy. I was told that I had an immunologic response and was dismissed. The pain lasted for 5 days and decreased as time went on. I continued to take over the counter medication to manage pain and decrease fever. I then switched care providers to Dr. who is my General Practitioner. She has advised that I do not take a repeat dose of Tdap vaccine.
Every time i have had a vaccine or booster i would get "useless arm syndrome".my lifting capacity would drop in the arm (by about 30 percent to 50 percent, or more...); It got so bad my should took over for lifting to the point where I nearly hurt my shoulder; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID. The reporter is the patient.  A male patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MUSCULAR WEAKNESS (non-serious), outcome "not recovered", described as "Every time i have had a vaccine or booster i would get "useless arm syndrome"."; JOINT RANGE OF MOTION DECREASED (non-serious), outcome "not recovered", described as "my lifting capacity would drop in the arm (by about 30 percent to 50 percent, or more...)"; LIMB INJURY (non-serious), outcome "not recovered", described as "It got so bad my should took over for lifting to the point where I nearly hurt my shoulder".  Additional information: It was reported that, the patient was messaging to find out if Pfizer/Biontech had fixed an issue with the covid-19 vaccine. Every time he had a vaccine or booster the reporter would get a useless arm syndrome. His lifting capacity would drop in the arm (by about 30% to 50% or more) that it was given in for 3-4 days after day 2 of the vaccine being in the arm. Yes, he had already reported this side effect. So, had this been fixed yet.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202200075548 same patient/events, different vaccine;
Heavy fatigue, difficulty sleeping, mild headache. The vaccine seemed to amplify the fatigue I was already feeling because I was not getting my Levothyroxine. The latter issue is fixed, but I'm guessing it will be a couple more days before my body gets back to normal.
PATIENT REPORTED THAT HE LOST CONSCIOUSNESS AFTER WAKING UP IN THE MIDDLE OF THE NIGHT THE DAY FOLLOWING VACCINATION. HE CALLED EMERGENCY AND WAS TAKEN TO THE ER WHERE LABS WERE RUN AND DETERMINDED THAT HE IS IN OTHERWISE GOOD HEALTH. PATIENT CONFIRMED THAT THE ER REMOVED ONE OF HIS BLOOD PRESSURE MEDICATIONS AS A RESULT OF THIS EVENT. PATIENT IS NOW HOME AND IN STABLE CONDITION.
Pt had fever that developed the morning after administration of the vaccines and persisted for about 24 hours, and she was very fussy the following day.
feet touching cold water or anything like air condition my hands; allergies to your hands and feet; feet get hives when they get cold from ice are air conditioners or cold water; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL COLDNESS (feet touching cold water or anything like air condition my hands), HYPERSENSITIVITY (allergies to your hands and feet) and URTICARIA (feet get hives when they get cold from ice are air conditioners or cold water) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PERIPHERAL COLDNESS (feet touching cold water or anything like air condition my hands), HYPERSENSITIVITY (allergies to your hands and feet) and URTICARIA (feet get hives when they get cold from ice are air conditioners or cold water). At the time of the report, PERIPHERAL COLDNESS (feet touching cold water or anything like air condition my hands), HYPERSENSITIVITY (allergies to your hands and feet) and URTICARIA (feet get hives when they get cold from ice are air conditioners or cold water) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication provided. No treatment information provided.   This case was linked to MOD-2021-281485 (Patient Link).
Pt recvd vax & began to exp a serum sickness type react consisting of joint pain, weakness &/or diarrhea; workup has included numerous tests for collagen vascular diseases & been non-diagnostic;
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. No information was provided regarding concurrent conditions, medical history, or concomitant medications. On or about 30-AUG-2012, the patient's healthcare provider at a primary care office administered ZOSTAVAX to the patient to obtain permanent prevention and protection against shingles and zoster-related injuries/conditions (dose, route, and lot # not provided). On or about 09-FEB-2017, the patient was treated by a physician at a primary care office for Bell's palsy and shingles. The patient was diagnosed with Bell's palsy and shingles and/or other zoster-related injuries after and despite being inoculated with ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of ZOSTAVAX, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was not recovered. Causality assessment was related. Upon internal review, Bell's palsy was considered to be medically significant. Additional information has been requested.
Suspected vaccination failure; I HAD THE SHOTS and still got it twice; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a adult patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.  Additional details were provided as follows: The reporter was the patient. The age at vaccination was not reported. The age group was not reported but was captured as adult as per vaccine indication. The patient received Shingles vaccine and still experienced shingles twice. The patient stated it was worst ever and living . This case was considered as suspected vaccination failure as details regarding time to onset for target disease and laboratory confirmation were unknown at the time of reporting.
Anaphylaxis Narrative:  Received 1st dose of Moderna COVID-19 vaccine at approximately 1203 and at 1235 reported feeling tingling to tongue and throat and difficulty swallowing. Respirations 28/min, heart rate 132, SaO2 100% room air. Taken to  emergency room and given 50 mg Benadryl IVP followed by 125 mg MethylPrednisone. Monitored in ER x 2.5 hours, Symptoms 100% resolved at  discharge.   Other Relevant History:
Presented for hypoxia, s/s COVID, COVID exposure. Hx Type II DM, HTN. Tx w/abx, zinc, TOCI, steroid, remdesivir, O2 via BiPAP and HFNC - weaned down to NC. DC'd to home.
Narrative:  HOSPITALIZED FOR COVID-19 INFECTION AFTER FULL VACCINATION. Patient is a 81 year old MALE brought in by wife due to oxygen desaturations at home on room air, patient started desaturating to 86%. Patient does have a cough with yellow sputum production. He states he does not feel short of breath worse than usual. No chest pain. No nausea or vomiting. Positive change in sense of smell and taste. Poor appetite rate and poor fluid intake. Patient is weak, tired and fatigued. Positive myalgias or arthralgias. No diarrhea. No abdominal pain. No dysuria. No leg swelling. Patient was diagnosed on July 18, 2021, with his symptoms beginning a day or 2 for that. No fevers or chills. No sweats. Does have some mild lightheadedness and dizziness with standing which resolves fairly quickly. No falls or syncope. His wife brought him in due to oxygen desaturations. Wife was trying to keep patient at home. Patient does appear to be searching for answers and was relying on his wife to answer many questions. HOSPITAL COURSE: This is an 81 yo Male patient with PMH of HTN,Hypothyroidism ,Chronic DVT and Pulmonary Embolism on Enoxaparin , Metastatic Prostate CA to liver and Bones s/p XRT,admitted after recently diagnosed with COVID + seen 7/18 /21 at ED onset of Mental status change with negative Head CT scan sent home and returned 07/25/2021 for hypoxemia O2 sat at RA ~ 86% hence admitted.At ED repeat CXRAY : + moderate Opacities Acute Mental status change likely 2/2 Metabolic Encephalopathy (hypoxemia and COVID Pneumonia with UTI and possibly medications (on Quetiapine and Trazodone): stable aCUTE RESPIRATORY FAILURE D/T COVID PNEUMONIA. PATIENT TREATED AND RECOVERED, DISCHARGED TO HOME.
Bad reaction/scary/ouch; This case was reported by a consumer via interactive digital media and described the occurrence of feeling bad in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced feeling bad. On an unknown date, the outcome of the feeling bad was unknown.   The reporter considered the feeling bad to be related to Shingles vaccine.  Additional details were provided as follows: The reporter was the patient. The age at vaccination was not reported. The patient had received the vaccine and got a bad reaction which was scary. The patient stated that there would be no second shingle vaccine for him/her.
This spontaneous report was received from a licensed vocational nurse refers to unspecified number of patients of unknown age and gender. The patient's concurrent conditions and medical history were not provided. On unspecified date, in 2015, reported as "since the first execution, which occurred on an unspecified date in August 2015", the patients were vaccinated with unspecified doses of PNEUMOVAX 23 lot # K008410 and expiration date 26-FEB-2016, (route of administration and anatomical location were not reported); the doses were exposed to temperatures outside of the recommended range. There were no concomitant medications reported. No adverse experiences had been reported. There was no product quality issue involved. This is one case of several cases from the same reporter. Additional information has been requested.
Sore arm, pain in the arm pit up to neck area, unable to use arm properly.
The report was first received from a practice manager on 07-SEP-2018, and it was recognized as non-valid because report did not obtain any patient identify. Follow-up information has been received from the practice manager on 18-SEP-2018. This spontaneous report refers to a patient of unknown age and gender. Information of concurrent condition, medical history and concomitant therapy was not provided. On 26-MAR-2018, the patient was vaccinated with an improperly stored dose of M-M-R II (recombinant human albumin) (strength was unknown) (lot# N013295 and expiration date 28-APR-2019) subcutaneously for prophylaxis. The MERCK STERILE DILUENT was properly stored. No adverse event was reported. The excursion temperature on 22-SEP-2017, 17-OCT-2017, 06-DEC-2017, 07-DEC-2017; 30-JAN-2018, 23-FEB-2018, 18-MAY-2018, 07-JUL-2018, 15-AUG-2018 was 6 degree Celsius for maximize 8.75 hours. The excursion temperature on 02-MAR-2018, 27-AUG-2018 was 7 degree Celsius for maximize 8.75 hours. The excursion temperature on 07-DEC-2017 was 8 degree Celsius for maximize 15 hours. The call was not because of data logger. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1809USA003709: US-009507513-1810USA001951: US-009507513-1810USA001952: US-009507513-1810USA001953: US-009507513-1810USA001954: US-009507513-1810USA001955: US-009507513-1810USA001956: US-009507513-1810USA001957: US-009507513-1810USA001958.
This spontaneous report as received from a registered nurse refers to a 14 year old male patient. The patient's relevant medical history and concomitant medications were not reported. On 29-APR-2015 (reported as "yesterday"), the patient was vaccinated intramuscularly with an adult dose of VAQTA (1 ml in right upper arm, lot # L001627, expiration date 11-NOV-2015), instead of the pediatric dose. No adverse effects were reported. No PQC (product quality complaint was involved. Additional information is not expected, as there was no consent for further contact.
Alopecia; This case was reported by a other health professional via call center representative and described the occurrence of alopecia in a 52-year-old male patient who received HBV (Engerix B) for prophylaxis.   Co-suspect products included Hepatitis A vaccine for prophylaxis, Typhoid vaccine for prophylaxis and diphtheria toxoid + pertussis toxoid acellular + tetanus toxoid (Tdap) for prophylaxis.   Concomitant products included HBV (Engerix B).   On 25th February 2019, the patient received the 2nd dose of Engerix B. On an unknown date, the patient received Hepatitis A vaccine at an unknown dose, Typhoid vaccine at an unknown dose and Tdap at an unknown dose and frequency. In March 2019, 14 days after receiving Engerix B and unknown after receiving Hepatitis A vaccine and Typhoid vaccine, the patient experienced alopecia. The patient was treated with medication unknown (Unspecified Medication). On an unknown date, the outcome of the alopecia was unknown.   The reporter considered the alopecia to be possibly related to Engerix B. It was unknown if the reporter considered the alopecia to be related to Hepatitis A vaccine and Typhoid vaccine.  Additional details were provided as follows: On 21st January 2019, the patent received the 1st dose of Engerix-B.  The healthcare professional noted the patient received Hep B, Hep A, TDap and typhoid vaccines when at the office. Brand name of the Hep A, TDap, and typhoid vaccines were not provided at the time of this call. About two weeks after receiving his 2nd dose of Engerix-B, the patient reported the alopecia.  The patient was upset because he was having alopecia. The patient had started a very expensive medication to treat it (medication not otherwise specified).  The healthcare professional stated the patient was threatening to sue the clinic for not stating that alopecia was a side effect.  The patient believed the Engerix-B caused the alopecia. It was unknown if the reporter considered the alopecia to be related to TDap vaccine.
Developed Bell's Palsy two days after Fluzone vaccine. The medical record received on 12/10/03 states laryngitis. Medical records sttes ear pain. msv